Why the study?
Does adenovirus-based phospholamban antisense expression improve Ca(2+) handling in cultured rat neonatal cardiomyocytes?
Population
Cultured rat neonatal cardiomyocytes
Comparison
Adenovectors expressing phospholamban antisense… vs Adenovectors expressing PL sense RNA or baseline
Design
Preclinical
Follow-up
up to 72 hours
Key result
Infection of cultured rat neonatal cardiomyocytes with Ad5CMVPLas reduced PL mRNA to 30% and PL protein to 24% of baseline, increasing Ca2+ sensitivity of SERCA2.
Authors
Loading...
May improve diastolic function via PL antisense; leaves open clinical translation in human HF.
Does adenovirus-based phospholamban antisense expression improve Ca(2+) handling in cultured rat neonatal cardiomyocytes?
Adenovirus-mediated phospholamban antisense RNA expression successfully downregulates phospholamban and improves calcium handling in cardiomyocytes, suggesting a potential gene therapy approach for heart failure.
Eizema et al. (2000) studied Cardiac contractile dysfunction. Adenovirus-based phospholamban (PL) antisense RNA (Ad5CMVPLas and Ad5ANFPLas) vs. Adenovectors expressing PL sense RNA (Ad5CMVPLs and Ad5ANFPLs) was evaluated on PL mRNA and protein levels. Infection of cultured rat neonatal cardiomyocytes with Ad5CMVPLas reduced PL mRNA to 30% and PL protein to 24% of baseline, increasing Ca2+ sensitivity of SERCA2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: